Cc Peptide
Lab Reagents
Cc Laboratories manufactures the cc peptide reagents distributed by Genprice. The Cc Peptide reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Cc. Other Cc products are available in stock. Specificity: Cc Category: Peptide
CC-90003 |
|||
B2419-5 | Biovision | each | EUR 496.8 |
CC-115 |
|||
B2499-25 | Biovision | each | EUR 757.2 |
CC-115 |
|||
B2499-5 | Biovision | each | EUR 235.2 |
Lenalidomide (CC-5013) |
|||
A4211-100 | ApexBio | 100 mg | EUR 226.8 |
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. |
Lenalidomide (CC-5013) |
|||
A4211-250 | ApexBio | 250 mg | EUR 268.8 |
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. |
Lenalidomide (CC-5013) |
|||
A4211-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 135.6 |
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. |
Lenalidomide (CC-5013) |
|||
A4211-50 | ApexBio | 50 mg | EUR 184.8 |
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. |
Lenalidomide (CC-5013) |
|||
A4211-500 | ApexBio | 500 mg | EUR 309.6 |
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. |
Lenalidomide (CC-5013) |
|||
A4211-S | ApexBio | Evaluation Sample | EUR 97.2 |
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. |
Pomalidomide (CC-4047) |
|||
A4212-10 | ApexBio | 10 mg | EUR 170.4 |
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM). |
Pomalidomide (CC-4047) |
|||
A4212-200 | ApexBio | 200 mg | EUR 964.8 |
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM). |
Pomalidomide (CC-4047) |
|||
A4212-5 | ApexBio | 5 mg | EUR 129.6 |
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM). |
Pomalidomide (CC-4047) |
|||
A4212-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 135.6 |
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM). |
Pomalidomide (CC-4047) |
|||
A4212-50 | ApexBio | 50 mg | EUR 351.6 |
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM). |
Pomalidomide (CC-4047) |
|||
A4212-S | ApexBio | Evaluation Sample | EUR 97.2 |
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM). |
Apremilast (CC-10004) |
|||
A4317-10 | ApexBio | 10 mg | EUR 268.8 |
Description: Apremilast, also known as CC-10004, is a novel and potent small-molecule inhibitor of phosphodiesterase 4 (PDE4), a key enzyme involved in cyclic adenosine monophosphate (cAMP) degradation and cytokine production of inflammatory cells. |
Apremilast (CC-10004) |
|||
A4317-25 | ApexBio | 25 mg | EUR 338.4 |
Description: Apremilast, also known as CC-10004, is a novel and potent small-molecule inhibitor of phosphodiesterase 4 (PDE4), a key enzyme involved in cyclic adenosine monophosphate (cAMP) degradation and cytokine production of inflammatory cells. |